GMP Compliant Production of a Cryopreserved Adipose-Derived Stromal Cell Product for Feasible and Allogeneic Clinical Use.
Mandana Haack-SørensenEllen Mønsted JohansenLisbeth Drozd HøjgaardJens KastrupAnnette EkblondPublished in: Stem cells international (2022)
The emerging field of advanced therapy medicinal products (ATMP) holds promise of treating a variety of diseases. Adipose-derived stromal cells (ASCs) are currently being marketed or tested as cell-based therapies in numerous clinical trials. To ensure safety and efficacy of treatments, high-quality products must be manufactured. A good manufacturing practice (GMP) compliant and consistent manufacturing process including validated quality control methods is critical. Product design and formulation are equally important to ensure clinical feasibility. Here, we present a GMP-compliant, xeno-free, and semiautomated manufacturing process and quality controls, used for large-scale production of a cryopreserved off-the-shelf ASC product and tested in several phase I and II allogeneic clinical applications.
Keyphrases
- quality control
- bone marrow
- stem cell transplantation
- clinical trial
- single cell
- biofilm formation
- cell therapy
- primary care
- healthcare
- umbilical cord
- drug delivery
- mesenchymal stem cells
- stem cells
- randomized controlled trial
- escherichia coli
- low dose
- big data
- pseudomonas aeruginosa
- staphylococcus aureus
- artificial intelligence
- open label